Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lantheus Holdings, Inc.

< Previous 1 2 Next >
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers DVAX LNTH
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports Second Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Appoints Jamie Spaeth as Chief People Officer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the William Blair 44th Annual Growth Stock Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Executive Appointments to Accelerate Innovation
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports First Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces CEO Succession Plan
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.